Evidence map›Paper›PMID 31337142›Full record

ArticleCancers2019

Docosahexaenoic Acid Enhances Oxaliplatin-Induced Autophagic Cell Death via the ER Stress/Sesn2 Pathway in Colorectal Cancer.

Soyeon Jeong, Dae Yeong Kim, Sang Hee Kang, Hye Kyeong Yun, Jung Lim Kim, Bo Ram Kim, Seong Hye Park, Yoo Jin Na, Min Jee Jo, Yoon A Jeong and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Genes · 2023
    Article
  13. Article
  14. Sestrin2 in cancer: a foe or a friend?Biomarker research · 2022
    Review
  15. The functions and roles of sestrins in regulating human diseases.Cellular & molecular biology letters · 2022
    Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Sestrin2-Mediated Autophagy Contributes to Drug ResistanceFrontiers in cell and developmental biology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Soyeon JeongDepartment of Oncology, Korea University Guro Hospital, Korea University College of Medicine, Seoul 08308, Korea.ORCID 0000-0002-4568-4579
Dae Yeong KimGraduate School of Medicine, College of Medicine, Korea University, Seoul 08308, Korea.
Sang Hee KangDepartment of Surgery, Korea University Guro Hospital, Korea University College of Medicine, Seoul 08308, Korea.ORCID 0000-0002-6097-8831
Hye Kyeong YunGraduate School of Medicine, College of Medicine, Korea University, Seoul 08308, Korea.
Jung Lim KimDepartment of Oncology, Korea University Guro Hospital, Korea University College of Medicine, Seoul 08308, Korea.
Bo Ram KimDepartment of Oncology, Korea University Guro Hospital, Korea University College of Medicine, Seoul 08308, Korea.
Seong Hye ParkGraduate School of Medicine, College of Medicine, Korea University, Seoul 08308, Korea.
Yoo Jin NaGraduate School of Medicine, College of Medicine, Korea University, Seoul 08308, Korea.
Min Jee JoGraduate School of Medicine, College of Medicine, Korea University, Seoul 08308, Korea.
Yoon A JeongGraduate School of Medicine, College of Medicine, Korea University, Seoul 08308, Korea.
Bu Gyeom KimGraduate School of Medicine, College of Medicine, Korea University, Seoul 08308, Korea.
Dae-Hee LeeDepartment of Oncology, Korea University Guro Hospital, Korea University College of Medicine, Seoul 08308, Korea. neogene@korea.ac.kr.
Sang Cheul OhDepartment of Oncology, Korea University Guro Hospital, Korea University College of Medicine, Seoul 08308, Korea. sachoh@korea.ac.kr.
Korea University · KRKorea University Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxaliplatin is an anticancer drug administered to colorectal cancer (CRC) patients in combination with 5-fluorouracil and antibodies (bevacizumab and cetuximab), thereby significantly improving the survival rate of CRC. However, due to various side effects associated with the above treatment strategy, the need for combinatorial therapeutic strategies has emerged. Based on the demand for new combinatorial therapies and the known antitumor effects of the omega-3 polyunsaturated fatty acid, docosahexaenoic acid (DHA), we investigated the Oxaliplatin and DHA combination for its effect. Our results indicated that DHA further enhanced Oxaliplatin-induced cell viability and autophagic cell death, in vitro and in vivo. Oxaliplatin and DHA also increased the expression of Sestrin 2 (SESN2) and endoplasmic reticulum (ER) stress related C/EBP homologous protein (CHOP). Additionally, treatment with Oxaliplatin and DHA enhanced the binding of CHOP to the promotor region of SESN2, increasing SESN2 expression. These results suggested that DHA enhanced Oxaliplatin-induced reduction in cell viability and increase in autophagy via activating SESN2 and increasing ER stress. Thus, SESN2 may be an effective preclinical target for CRC treatment.

Indexed as

autophagic cell deathcolon cancerdocosahexaenoic acidOxaliplatinSestrin 2

Identifiers

PMID31337142
PMCPMC6678695
OpenAlexW2957653455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.